nodes	percent_of_prediction	percent_of_DWPC	metapath
Alvimopan—Hypokalaemia—Abiraterone—prostate cancer	0.0157	0.0221	CcSEcCtD
Alvimopan—Urinary retention—Cabazitaxel—prostate cancer	0.0126	0.0178	CcSEcCtD
Alvimopan—Hypokalaemia—Cabazitaxel—prostate cancer	0.0121	0.017	CcSEcCtD
Alvimopan—Urinary tract disorder—Abiraterone—prostate cancer	0.0118	0.0166	CcSEcCtD
Alvimopan—Connective tissue disorder—Abiraterone—prostate cancer	0.0117	0.0165	CcSEcCtD
Alvimopan—Urethral disorder—Abiraterone—prostate cancer	0.0117	0.0165	CcSEcCtD
Alvimopan—Urinary retention—Bicalutamide—prostate cancer	0.0108	0.0153	CcSEcCtD
Alvimopan—Urinary tract disorder—Nilutamide—prostate cancer	0.0108	0.0152	CcSEcCtD
Alvimopan—Urethral disorder—Nilutamide—prostate cancer	0.0107	0.0151	CcSEcCtD
Alvimopan—Flatulence—Estramustine—prostate cancer	0.0105	0.0149	CcSEcCtD
Alvimopan—Flatulence—Estrone—prostate cancer	0.0101	0.0142	CcSEcCtD
Alvimopan—Connective tissue disorder—Estradiol valerate/Dienogest—prostate cancer	0.0101	0.0142	CcSEcCtD
Alvimopan—Urinary tract disorder—Degarelix—prostate cancer	0.00962	0.0136	CcSEcCtD
Alvimopan—Anaemia—Abiraterone—prostate cancer	0.00961	0.0135	CcSEcCtD
Alvimopan—Urethral disorder—Degarelix—prostate cancer	0.00955	0.0135	CcSEcCtD
Alvimopan—Back pain—Nilutamide—prostate cancer	0.00919	0.013	CcSEcCtD
Alvimopan—Urinary tract disorder—Cabazitaxel—prostate cancer	0.00907	0.0128	CcSEcCtD
Alvimopan—Connective tissue disorder—Cabazitaxel—prostate cancer	0.00902	0.0127	CcSEcCtD
Alvimopan—Urethral disorder—Cabazitaxel—prostate cancer	0.009	0.0127	CcSEcCtD
Alvimopan—Malnutrition—Estradiol valerate/Dienogest—prostate cancer	0.00892	0.0126	CcSEcCtD
Alvimopan—Flatulence—Estradiol valerate/Dienogest—prostate cancer	0.00879	0.0124	CcSEcCtD
Alvimopan—Anaemia—Nilutamide—prostate cancer	0.00878	0.0124	CcSEcCtD
Alvimopan—Anaemia—Flutamide—prostate cancer	0.00874	0.0123	CcSEcCtD
Alvimopan—Malnutrition—Degarelix—prostate cancer	0.00848	0.012	CcSEcCtD
Alvimopan—Back pain—Degarelix—prostate cancer	0.00821	0.0116	CcSEcCtD
Alvimopan—Malnutrition—Cabazitaxel—prostate cancer	0.00799	0.0113	CcSEcCtD
Alvimopan—Anaemia—Degarelix—prostate cancer	0.00784	0.0111	CcSEcCtD
Alvimopan—Urinary tract disorder—Bicalutamide—prostate cancer	0.00778	0.011	CcSEcCtD
Alvimopan—Back pain—Cabazitaxel—prostate cancer	0.00773	0.0109	CcSEcCtD
Alvimopan—Urethral disorder—Bicalutamide—prostate cancer	0.00772	0.0109	CcSEcCtD
Alvimopan—Urinary retention—Goserelin—prostate cancer	0.00753	0.0106	CcSEcCtD
Alvimopan—Dyspepsia—Abiraterone—prostate cancer	0.00747	0.0105	CcSEcCtD
Alvimopan—Anaemia—Cabazitaxel—prostate cancer	0.00739	0.0104	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Abiraterone—prostate cancer	0.00732	0.0103	CcSEcCtD
Alvimopan—Constipation—Abiraterone—prostate cancer	0.00725	0.0102	CcSEcCtD
Alvimopan—Hypokalaemia—Conjugated Estrogens—prostate cancer	0.00714	0.0101	CcSEcCtD
Alvimopan—Malnutrition—Bicalutamide—prostate cancer	0.00685	0.00967	CcSEcCtD
Alvimopan—Dyspepsia—Nilutamide—prostate cancer	0.00682	0.00962	CcSEcCtD
Alvimopan—Flatulence—Bicalutamide—prostate cancer	0.00675	0.00952	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Nilutamide—prostate cancer	0.00669	0.00943	CcSEcCtD
Alvimopan—Back pain—Bicalutamide—prostate cancer	0.00663	0.00935	CcSEcCtD
Alvimopan—Constipation—Nilutamide—prostate cancer	0.00663	0.00934	CcSEcCtD
Alvimopan—Constipation—Flutamide—prostate cancer	0.0066	0.0093	CcSEcCtD
Alvimopan—Urinary tract disorder—Ethinyl Estradiol—prostate cancer	0.00657	0.00927	CcSEcCtD
Alvimopan—Connective tissue disorder—Ethinyl Estradiol—prostate cancer	0.00654	0.00922	CcSEcCtD
Alvimopan—Urethral disorder—Ethinyl Estradiol—prostate cancer	0.00652	0.0092	CcSEcCtD
Alvimopan—Dyspepsia—Estradiol valerate/Dienogest—prostate cancer	0.00641	0.00904	CcSEcCtD
Alvimopan—Anaemia—Bicalutamide—prostate cancer	0.00634	0.00893	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.00629	0.00886	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Degarelix—prostate cancer	0.00598	0.00843	CcSEcCtD
Alvimopan—Constipation—Degarelix—prostate cancer	0.00592	0.00835	CcSEcCtD
Alvimopan—Malnutrition—Ethinyl Estradiol—prostate cancer	0.00579	0.00817	CcSEcCtD
Alvimopan—Dyspepsia—Cabazitaxel—prostate cancer	0.00574	0.00809	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.00563	0.00794	CcSEcCtD
Alvimopan—Back pain—Ethinyl Estradiol—prostate cancer	0.0056	0.0079	CcSEcCtD
Alvimopan—Constipation—Cabazitaxel—prostate cancer	0.00558	0.00786	CcSEcCtD
Alvimopan—Indinavir—SLC22A1—prostate cancer	0.00545	0.176	CrCbGaD
Alvimopan—Urinary tract disorder—Goserelin—prostate cancer	0.00541	0.00763	CcSEcCtD
Alvimopan—Urethral disorder—Goserelin—prostate cancer	0.00537	0.00757	CcSEcCtD
Alvimopan—Hypokalaemia—Mitoxantrone—prostate cancer	0.00532	0.00751	CcSEcCtD
Alvimopan—Dyspepsia—Bicalutamide—prostate cancer	0.00492	0.00694	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.00483	0.00681	CcSEcCtD
Alvimopan—Constipation—Bicalutamide—prostate cancer	0.00478	0.00675	CcSEcCtD
Alvimopan—Malnutrition—Goserelin—prostate cancer	0.00477	0.00672	CcSEcCtD
Alvimopan—Malnutrition—Conjugated Estrogens—prostate cancer	0.00472	0.00666	CcSEcCtD
Alvimopan—Flatulence—Goserelin—prostate cancer	0.0047	0.00663	CcSEcCtD
Alvimopan—Flatulence—Conjugated Estrogens—prostate cancer	0.00465	0.00656	CcSEcCtD
Alvimopan—Back pain—Goserelin—prostate cancer	0.00461	0.0065	CcSEcCtD
Alvimopan—Back pain—Conjugated Estrogens—prostate cancer	0.00457	0.00644	CcSEcCtD
Alvimopan—Benazepril—MTHFR—prostate cancer	0.00447	0.144	CrCbGaD
Alvimopan—Anaemia—Goserelin—prostate cancer	0.00441	0.00621	CcSEcCtD
Alvimopan—Indinavir—CYP3A5—prostate cancer	0.0044	0.142	CrCbGaD
Alvimopan—Urinary tract disorder—Estradiol—prostate cancer	0.00429	0.00605	CcSEcCtD
Alvimopan—Connective tissue disorder—Estradiol—prostate cancer	0.00427	0.00602	CcSEcCtD
Alvimopan—Urethral disorder—Estradiol—prostate cancer	0.00426	0.006	CcSEcCtD
Alvimopan—Quinapril—ACE—prostate cancer	0.00418	0.135	CrCbGaD
Alvimopan—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.00408	0.00576	CcSEcCtD
Alvimopan—Constipation—Ethinyl Estradiol—prostate cancer	0.00404	0.0057	CcSEcCtD
Alvimopan—Malnutrition—Estradiol—prostate cancer	0.00378	0.00533	CcSEcCtD
Alvimopan—Flatulence—Estradiol—prostate cancer	0.00373	0.00525	CcSEcCtD
Alvimopan—Urinary retention—Capecitabine—prostate cancer	0.00372	0.00525	CcSEcCtD
Alvimopan—Back pain—Estradiol—prostate cancer	0.00366	0.00516	CcSEcCtD
Alvimopan—Benazepril—ACE—prostate cancer	0.00364	0.117	CrCbGaD
Alvimopan—Hypokalaemia—Capecitabine—prostate cancer	0.00356	0.00502	CcSEcCtD
Alvimopan—Dyspepsia—Goserelin—prostate cancer	0.00343	0.00483	CcSEcCtD
Alvimopan—Back pain—Mitoxantrone—prostate cancer	0.00341	0.0048	CcSEcCtD
Alvimopan—Dyspepsia—Conjugated Estrogens—prostate cancer	0.00339	0.00478	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.00333	0.00469	CcSEcCtD
Alvimopan—Constipation—Goserelin—prostate cancer	0.00333	0.00469	CcSEcCtD
Alvimopan—Urinary tract disorder—Etoposide—prostate cancer	0.00332	0.00469	CcSEcCtD
Alvimopan—Urethral disorder—Etoposide—prostate cancer	0.0033	0.00465	CcSEcCtD
Alvimopan—Constipation—Conjugated Estrogens—prostate cancer	0.0033	0.00465	CcSEcCtD
Alvimopan—Anaemia—Mitoxantrone—prostate cancer	0.00326	0.00459	CcSEcCtD
Alvimopan—Hypokalaemia—Prednisone—prostate cancer	0.00317	0.00447	CcSEcCtD
Alvimopan—Ketoprofen—CXCL8—prostate cancer	0.00307	0.099	CrCbGaD
Alvimopan—Indinavir—CYP2C19—prostate cancer	0.00299	0.0966	CrCbGaD
Alvimopan—Back pain—Etoposide—prostate cancer	0.00283	0.004	CcSEcCtD
Alvimopan—Urinary tract disorder—Docetaxel—prostate cancer	0.00276	0.00389	CcSEcCtD
Alvimopan—Connective tissue disorder—Docetaxel—prostate cancer	0.00275	0.00388	CcSEcCtD
Alvimopan—Urethral disorder—Docetaxel—prostate cancer	0.00274	0.00387	CcSEcCtD
Alvimopan—Dyspepsia—Estradiol—prostate cancer	0.00272	0.00383	CcSEcCtD
Alvimopan—Anaemia—Etoposide—prostate cancer	0.00271	0.00382	CcSEcCtD
Alvimopan—Urinary tract disorder—Capecitabine—prostate cancer	0.00267	0.00377	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Estradiol—prostate cancer	0.00266	0.00376	CcSEcCtD
Alvimopan—Connective tissue disorder—Capecitabine—prostate cancer	0.00266	0.00375	CcSEcCtD
Alvimopan—Urethral disorder—Capecitabine—prostate cancer	0.00265	0.00374	CcSEcCtD
Alvimopan—Constipation—Estradiol—prostate cancer	0.00264	0.00372	CcSEcCtD
Alvimopan—Dyspepsia—Mitoxantrone—prostate cancer	0.00253	0.00357	CcSEcCtD
Alvimopan—Hypokalaemia—Epirubicin—prostate cancer	0.00248	0.0035	CcSEcCtD
Alvimopan—Constipation—Mitoxantrone—prostate cancer	0.00246	0.00347	CcSEcCtD
Alvimopan—Malnutrition—Docetaxel—prostate cancer	0.00243	0.00343	CcSEcCtD
Alvimopan—Connective tissue disorder—Prednisone—prostate cancer	0.00237	0.00334	CcSEcCtD
Alvimopan—Malnutrition—Capecitabine—prostate cancer	0.00236	0.00332	CcSEcCtD
Alvimopan—Back pain—Docetaxel—prostate cancer	0.00236	0.00332	CcSEcCtD
Alvimopan—Flatulence—Capecitabine—prostate cancer	0.00232	0.00328	CcSEcCtD
Alvimopan—Hypokalaemia—Doxorubicin—prostate cancer	0.0023	0.00324	CcSEcCtD
Alvimopan—Back pain—Capecitabine—prostate cancer	0.00228	0.00322	CcSEcCtD
Alvimopan—Anaemia—Docetaxel—prostate cancer	0.00225	0.00317	CcSEcCtD
Alvimopan—Anaemia—Capecitabine—prostate cancer	0.00218	0.00307	CcSEcCtD
Alvimopan—Malnutrition—Prednisone—prostate cancer	0.0021	0.00296	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Etoposide—prostate cancer	0.00206	0.00291	CcSEcCtD
Alvimopan—Constipation—Etoposide—prostate cancer	0.00204	0.00288	CcSEcCtD
Alvimopan—Anaemia—Prednisone—prostate cancer	0.00194	0.00274	CcSEcCtD
Alvimopan—Indinavir—CYP3A4—prostate cancer	0.0019	0.0614	CrCbGaD
Alvimopan—Urinary tract disorder—Epirubicin—prostate cancer	0.00186	0.00263	CcSEcCtD
Alvimopan—Connective tissue disorder—Epirubicin—prostate cancer	0.00185	0.00261	CcSEcCtD
Alvimopan—Urethral disorder—Epirubicin—prostate cancer	0.00185	0.00261	CcSEcCtD
Alvimopan—Dyspepsia—Docetaxel—prostate cancer	0.00175	0.00247	CcSEcCtD
Alvimopan—Urinary tract disorder—Doxorubicin—prostate cancer	0.00172	0.00243	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Docetaxel—prostate cancer	0.00172	0.00242	CcSEcCtD
Alvimopan—Connective tissue disorder—Doxorubicin—prostate cancer	0.00172	0.00242	CcSEcCtD
Alvimopan—Urethral disorder—Doxorubicin—prostate cancer	0.00171	0.00241	CcSEcCtD
Alvimopan—Constipation—Docetaxel—prostate cancer	0.0017	0.0024	CcSEcCtD
Alvimopan—Dyspepsia—Capecitabine—prostate cancer	0.00169	0.00239	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Capecitabine—prostate cancer	0.00166	0.00234	CcSEcCtD
Alvimopan—Constipation—Capecitabine—prostate cancer	0.00165	0.00232	CcSEcCtD
Alvimopan—Malnutrition—Epirubicin—prostate cancer	0.00164	0.00232	CcSEcCtD
Alvimopan—Flatulence—Epirubicin—prostate cancer	0.00162	0.00228	CcSEcCtD
Alvimopan—Back pain—Epirubicin—prostate cancer	0.00159	0.00224	CcSEcCtD
Alvimopan—Malnutrition—Doxorubicin—prostate cancer	0.00152	0.00214	CcSEcCtD
Alvimopan—Anaemia—Epirubicin—prostate cancer	0.00152	0.00214	CcSEcCtD
Alvimopan—Dyspepsia—Prednisone—prostate cancer	0.00151	0.00213	CcSEcCtD
Alvimopan—Flatulence—Doxorubicin—prostate cancer	0.0015	0.00211	CcSEcCtD
Alvimopan—Back pain—Doxorubicin—prostate cancer	0.00147	0.00207	CcSEcCtD
Alvimopan—Constipation—Prednisone—prostate cancer	0.00147	0.00207	CcSEcCtD
Alvimopan—Anaemia—Doxorubicin—prostate cancer	0.0014	0.00198	CcSEcCtD
Alvimopan—Dyspepsia—Epirubicin—prostate cancer	0.00118	0.00166	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Epirubicin—prostate cancer	0.00116	0.00163	CcSEcCtD
Alvimopan—Constipation—Epirubicin—prostate cancer	0.00115	0.00162	CcSEcCtD
Alvimopan—Dyspepsia—Doxorubicin—prostate cancer	0.00109	0.00154	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.00107	0.00151	CcSEcCtD
Alvimopan—Constipation—Doxorubicin—prostate cancer	0.00106	0.0015	CcSEcCtD
Alvimopan—Ketoprofen—PTGS2—prostate cancer	0.000895	0.0289	CrCbGaD
Alvimopan—OPRD1—Signaling Pathways—PRKCQ—prostate cancer	0.000115	0.000443	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—FGFR4—prostate cancer	0.000115	0.000442	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PARP1—prostate cancer	0.000115	0.000442	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MAP3K7—prostate cancer	0.000114	0.000438	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CALCA—prostate cancer	0.000113	0.000436	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CXCL12—prostate cancer	0.000111	0.000426	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—FGF10—prostate cancer	0.000109	0.000421	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TGFBR1—prostate cancer	0.000109	0.000419	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PTHLH—prostate cancer	0.000109	0.000419	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ADRB2—prostate cancer	0.000108	0.000417	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—AKR1C3—prostate cancer	0.000107	0.000412	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—JAK2—prostate cancer	0.000107	0.000411	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PRKACB—prostate cancer	0.000106	0.00041	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—MAP2K1—prostate cancer	0.000106	0.00041	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—PIK3CD—prostate cancer	0.000106	0.000407	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—VAV3—prostate cancer	0.000106	0.000407	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—PIK3CG—prostate cancer	0.000105	0.000406	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CASP9—prostate cancer	0.000104	0.000401	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—TGFBR2—prostate cancer	0.000104	0.000401	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PPP3CA—prostate cancer	0.000104	0.0004	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—THBS1—prostate cancer	0.000104	0.0004	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ITPR1—prostate cancer	0.000102	0.000394	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ANXA1—prostate cancer	0.000102	0.000394	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—PIK3CD—prostate cancer	0.000102	0.000393	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—PIK3CB—prostate cancer	0.000101	0.000391	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PRKCQ—prostate cancer	0.000101	0.000389	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—NGFR—prostate cancer	0.000101	0.000389	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PRKCZ—prostate cancer	0.0001	0.000386	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MAP3K7—prostate cancer	9.98e-05	0.000384	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—PIK3CG—prostate cancer	9.81e-05	0.000378	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IGF1R—prostate cancer	9.79e-05	0.000377	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—CXCL8—prostate cancer	9.75e-05	0.000375	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—JAK2—prostate cancer	9.7e-05	0.000373	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PARP1—prostate cancer	9.7e-05	0.000373	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FGFR4—prostate cancer	9.7e-05	0.000373	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—FGF10—prostate cancer	9.6e-05	0.000369	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CALCA—prostate cancer	9.58e-05	0.000369	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ADRB2—prostate cancer	9.5e-05	0.000366	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—LPL—prostate cancer	9.39e-05	0.000361	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—JAK2—prostate cancer	9.37e-05	0.000361	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CXCL12—prostate cancer	9.35e-05	0.00036	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—MAP2K1—prostate cancer	9.33e-05	0.000359	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—IL2—prostate cancer	9.32e-05	0.000359	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PDGFRB—prostate cancer	9.31e-05	0.000358	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—PIK3CD—prostate cancer	9.27e-05	0.000357	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—VAV3—prostate cancer	9.26e-05	0.000356	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—PIK3CB—prostate cancer	9.21e-05	0.000355	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—TGFBR2—prostate cancer	9.13e-05	0.000351	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ITGB3—prostate cancer	9.07e-05	0.000349	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ITPR1—prostate cancer	8.98e-05	0.000346	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—PIK3CG—prostate cancer	8.91e-05	0.000343	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—PIK3CB—prostate cancer	8.9e-05	0.000342	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CXCL8—prostate cancer	8.85e-05	0.000341	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CASP9—prostate cancer	8.81e-05	0.000339	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ERBB3—prostate cancer	8.8e-05	0.000339	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—FGFR2—prostate cancer	8.78e-05	0.000338	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—PIK3CD—prostate cancer	8.63e-05	0.000332	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IGF1R—prostate cancer	8.59e-05	0.000331	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—CXCL8—prostate cancer	8.55e-05	0.000329	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PRKCQ—prostate cancer	8.54e-05	0.000329	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—NGFR—prostate cancer	8.54e-05	0.000329	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—JAK2—prostate cancer	8.51e-05	0.000327	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—IL2—prostate cancer	8.46e-05	0.000326	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MAP3K7—prostate cancer	8.43e-05	0.000325	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—TERT—prostate cancer	8.43e-05	0.000325	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—LPL—prostate cancer	8.23e-05	0.000317	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—IL2—prostate cancer	8.17e-05	0.000315	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PDGFRB—prostate cancer	8.16e-05	0.000314	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FGF10—prostate cancer	8.11e-05	0.000312	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—PIK3CB—prostate cancer	8.08e-05	0.000311	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—HIF1A—prostate cancer	8.06e-05	0.00031	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ADRB2—prostate cancer	8.03e-05	0.000309	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ITGB3—prostate cancer	7.95e-05	0.000306	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—JAK2—prostate cancer	7.92e-05	0.000305	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—MAP2K1—prostate cancer	7.89e-05	0.000304	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—LEP—prostate cancer	7.87e-05	0.000303	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—PIK3CD—prostate cancer	7.83e-05	0.000302	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—VAV3—prostate cancer	7.83e-05	0.000301	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CAV1—prostate cancer	7.8e-05	0.0003	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CXCL8—prostate cancer	7.76e-05	0.000299	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TGFBR2—prostate cancer	7.71e-05	0.000297	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ERBB3—prostate cancer	7.71e-05	0.000297	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—KDR—prostate cancer	7.71e-05	0.000297	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—FGFR2—prostate cancer	7.7e-05	0.000296	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ITPR1—prostate cancer	7.59e-05	0.000292	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—PIK3CB—prostate cancer	7.52e-05	0.000289	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ESR1—prostate cancer	7.51e-05	0.000289	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—IL2—prostate cancer	7.42e-05	0.000286	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—TERT—prostate cancer	7.39e-05	0.000285	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—BAD—prostate cancer	7.33e-05	0.000282	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IGF1R—prostate cancer	7.26e-05	0.000279	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—CXCL8—prostate cancer	7.23e-05	0.000278	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—JAK2—prostate cancer	7.19e-05	0.000277	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PIK3CG—prostate cancer	7.1e-05	0.000273	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—APC—prostate cancer	7.1e-05	0.000273	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—HIF1A—prostate cancer	7.07e-05	0.000272	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—EGF—prostate cancer	7.02e-05	0.00027	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IRS1—prostate cancer	7.02e-05	0.00027	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—LPL—prostate cancer	6.96e-05	0.000268	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—IL2—prostate cancer	6.91e-05	0.000266	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—LEP—prostate cancer	6.9e-05	0.000266	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PDGFRB—prostate cancer	6.9e-05	0.000265	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CAV1—prostate cancer	6.84e-05	0.000263	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—PIK3CB—prostate cancer	6.83e-05	0.000263	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—GSK3B—prostate cancer	6.82e-05	0.000262	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—KDR—prostate cancer	6.76e-05	0.00026	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—INS—prostate cancer	6.72e-05	0.000259	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ITGB3—prostate cancer	6.72e-05	0.000259	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ESR1—prostate cancer	6.59e-05	0.000254	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CREBBP—prostate cancer	6.59e-05	0.000254	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CXCL8—prostate cancer	6.56e-05	0.000253	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ERBB3—prostate cancer	6.52e-05	0.000251	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FGFR2—prostate cancer	6.51e-05	0.000251	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IGF1—prostate cancer	6.5e-05	0.00025	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—EGFR—prostate cancer	6.47e-05	0.000249	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—BAD—prostate cancer	6.43e-05	0.000248	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MAP2K1—prostate cancer	6.29e-05	0.000242	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—IL2—prostate cancer	6.27e-05	0.000241	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TERT—prostate cancer	6.25e-05	0.000241	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PIK3CD—prostate cancer	6.24e-05	0.00024	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PIK3CG—prostate cancer	6.23e-05	0.00024	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—APC—prostate cancer	6.23e-05	0.00024	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—PIK3CA—prostate cancer	6.19e-05	0.000238	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—SERPINE1—prostate cancer	6.18e-05	0.000238	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IRS1—prostate cancer	6.16e-05	0.000237	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—EGF—prostate cancer	6.16e-05	0.000237	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—KRAS—prostate cancer	6.11e-05	0.000235	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—FGF2—prostate cancer	5.98e-05	0.00023	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—GSK3B—prostate cancer	5.98e-05	0.00023	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—HIF1A—prostate cancer	5.98e-05	0.00023	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—NOS3—prostate cancer	5.9e-05	0.000227	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—INS—prostate cancer	5.9e-05	0.000227	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—LEP—prostate cancer	5.83e-05	0.000225	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CAV1—prostate cancer	5.78e-05	0.000222	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CREBBP—prostate cancer	5.77e-05	0.000222	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—JAK2—prostate cancer	5.73e-05	0.000221	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—KDR—prostate cancer	5.71e-05	0.00022	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IGF1—prostate cancer	5.7e-05	0.00022	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—EGFR—prostate cancer	5.67e-05	0.000218	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—PIK3CA—prostate cancer	5.62e-05	0.000216	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MDM2—prostate cancer	5.59e-05	0.000215	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ESR1—prostate cancer	5.57e-05	0.000214	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ERBB2—prostate cancer	5.52e-05	0.000212	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MAP2K1—prostate cancer	5.51e-05	0.000212	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PIK3CD—prostate cancer	5.48e-05	0.000211	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PIK3CB—prostate cancer	5.44e-05	0.00021	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—BAD—prostate cancer	5.44e-05	0.000209	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—PIK3CA—prostate cancer	5.42e-05	0.000209	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—SERPINE1—prostate cancer	5.42e-05	0.000208	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—KRAS—prostate cancer	5.36e-05	0.000206	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—APC—prostate cancer	5.26e-05	0.000203	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PIK3CG—prostate cancer	5.26e-05	0.000203	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—FGF2—prostate cancer	5.24e-05	0.000202	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CXCL8—prostate cancer	5.23e-05	0.000201	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IRS1—prostate cancer	5.2e-05	0.0002	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—EGF—prostate cancer	5.2e-05	0.0002	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—NOS3—prostate cancer	5.17e-05	0.000199	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CDKN1B—prostate cancer	5.11e-05	0.000197	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—AKT1—prostate cancer	5.05e-05	0.000195	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—GSK3B—prostate cancer	5.05e-05	0.000194	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—JAK2—prostate cancer	5.03e-05	0.000193	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CASP3—prostate cancer	5.01e-05	0.000193	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IL2—prostate cancer	5e-05	0.000192	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—INS—prostate cancer	4.98e-05	0.000192	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—IL6—prostate cancer	4.97e-05	0.000191	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—PIK3CA—prostate cancer	4.93e-05	0.00019	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MDM2—prostate cancer	4.91e-05	0.000189	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CREBBP—prostate cancer	4.88e-05	0.000188	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CCND1—prostate cancer	4.87e-05	0.000188	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ERBB2—prostate cancer	4.84e-05	0.000186	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CTNNB1—prostate cancer	4.83e-05	0.000186	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IGF1—prostate cancer	4.82e-05	0.000186	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—EGFR—prostate cancer	4.8e-05	0.000185	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PIK3CB—prostate cancer	4.77e-05	0.000184	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MMP9—prostate cancer	4.73e-05	0.000182	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CDKN1A—prostate cancer	4.71e-05	0.000181	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PTEN—prostate cancer	4.7e-05	0.000181	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MAP2K1—prostate cancer	4.66e-05	0.000179	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PIK3CD—prostate cancer	4.63e-05	0.000178	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—AKT1—prostate cancer	4.59e-05	0.000177	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CXCL8—prostate cancer	4.59e-05	0.000177	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—PIK3CA—prostate cancer	4.58e-05	0.000176	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—SERPINE1—prostate cancer	4.58e-05	0.000176	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—KRAS—prostate cancer	4.53e-05	0.000174	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—EP300—prostate cancer	4.49e-05	0.000173	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CDKN1B—prostate cancer	4.48e-05	0.000172	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FGF2—prostate cancer	4.43e-05	0.000171	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—AKT1—prostate cancer	4.43e-05	0.000171	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CASP3—prostate cancer	4.39e-05	0.000169	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IL2—prostate cancer	4.38e-05	0.000169	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—NOS3—prostate cancer	4.37e-05	0.000168	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—SRC—prostate cancer	4.36e-05	0.000168	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—IL6—prostate cancer	4.36e-05	0.000168	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CCND1—prostate cancer	4.27e-05	0.000164	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—VEGFA—prostate cancer	4.25e-05	0.000164	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—JAK2—prostate cancer	4.25e-05	0.000163	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CTNNB1—prostate cancer	4.23e-05	0.000163	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—STAT3—prostate cancer	4.21e-05	0.000162	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—PIK3CA—prostate cancer	4.16e-05	0.00016	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MMP9—prostate cancer	4.15e-05	0.00016	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MDM2—prostate cancer	4.15e-05	0.00016	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CDKN1A—prostate cancer	4.13e-05	0.000159	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PTEN—prostate cancer	4.12e-05	0.000159	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ERBB2—prostate cancer	4.09e-05	0.000157	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PIK3CB—prostate cancer	4.03e-05	0.000155	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—AKT1—prostate cancer	4.02e-05	0.000155	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—EP300—prostate cancer	3.93e-05	0.000151	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MYC—prostate cancer	3.91e-05	0.00015	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—TGFB1—prostate cancer	3.9e-05	0.00015	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CXCL8—prostate cancer	3.88e-05	0.000149	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—SRC—prostate cancer	3.82e-05	0.000147	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—EGFR—prostate cancer	3.82e-05	0.000147	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CDKN1B—prostate cancer	3.79e-05	0.000146	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—AKT1—prostate cancer	3.74e-05	0.000144	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—VEGFA—prostate cancer	3.73e-05	0.000143	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CASP3—prostate cancer	3.71e-05	0.000143	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IL2—prostate cancer	3.7e-05	0.000143	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—STAT3—prostate cancer	3.69e-05	0.000142	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—IL6—prostate cancer	3.69e-05	0.000142	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—KRAS—prostate cancer	3.61e-05	0.000139	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CCND1—prostate cancer	3.61e-05	0.000139	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CTNNB1—prostate cancer	3.58e-05	0.000138	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MMP9—prostate cancer	3.51e-05	0.000135	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CDKN1A—prostate cancer	3.49e-05	0.000134	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PTEN—prostate cancer	3.49e-05	0.000134	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MYC—prostate cancer	3.43e-05	0.000132	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—TGFB1—prostate cancer	3.42e-05	0.000132	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—AKT1—prostate cancer	3.4e-05	0.000131	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—EGFR—prostate cancer	3.35e-05	0.000129	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—EP300—prostate cancer	3.32e-05	0.000128	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PIK3CA—prostate cancer	3.32e-05	0.000128	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—SRC—prostate cancer	3.23e-05	0.000124	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—TP53—prostate cancer	3.21e-05	0.000124	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—KRAS—prostate cancer	3.17e-05	0.000122	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—VEGFA—prostate cancer	3.15e-05	0.000121	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—STAT3—prostate cancer	3.12e-05	0.00012	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IL6—prostate cancer	2.94e-05	0.000113	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	2.91e-05	0.000112	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MYC—prostate cancer	2.9e-05	0.000112	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TGFB1—prostate cancer	2.89e-05	0.000111	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—EGFR—prostate cancer	2.83e-05	0.000109	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—TP53—prostate cancer	2.81e-05	0.000108	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—AKT1—prostate cancer	2.71e-05	0.000104	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—KRAS—prostate cancer	2.68e-05	0.000103	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IL6—prostate cancer	2.58e-05	9.92e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	2.46e-05	9.47e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TP53—prostate cancer	2.38e-05	9.16e-05	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—AKT1—prostate cancer	2.38e-05	9.15e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IL6—prostate cancer	2.18e-05	8.38e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—AKT1—prostate cancer	2.01e-05	7.73e-05	CbGpPWpGaD
